Impact of a new palliative care consultation team on opioid prescription in a University Hospital

Carlos Centeno*1, María Angustias Portela1, Antonio Noguera2, Antonio Idoate3 and Álvaro Sanz Rubiales4

Address: 1Unidad de Medicina Paliativa y Control de Síntomas, Clínica Universidad de Navarra, Pamplona, Spain, 2Unidad de Medicina Paliativa, Hospital Laguna, Madrid, Spain, 3Departamento de Farmacia, Clínica Universidad de Navarra, Pamplona, Spain and 4Unidad de Oncología, Hospital Universitario del Río Hortega, Valladolid, Spain

Email: Carlos Centeno* - ccenteno@unav.es; María Angustias Portela - mportela@unav.es; Antonio Noguera - anoguera@lagunacuida.org; Antonio Idoate - aidoate@unav.es; Álvaro Sanz Rubiales - asrubiales@hotmail.com

* Corresponding author

Abstract

**Background:** There are no validated measuring tools to gauge the effectiveness of a Hospital Palliative Care Consultation Team (PCCT). One way would be to consider its effect on the consumption of opioids expressed in total amounts and different formulations administered. We perform this study to evaluate the impact of a hospital PCCT on the trends of opioid prescription in a University Hospital.

**Methods:** A seven year retrospective study on opioid prescription was carried out in the Clínica Universidad de Navarra. The period includes three years before and three years after the PCCT was implemented. Prescription was analysed calculating yearly the Defined Daily Dose (DDD) adjusted to 1000 hospital stays (DDD/1000HS). Indicators considered were the proportion of patients treated using opioids compared to the total estimated in need of treatment (rate of effectiveness) and the proportion of patients potentially requiring opioids but not treated who were incorporated into the treatment group (rate of improvement).

**Results:** From 2001 to 2007, total opioid prescription was low in non-oncology Departments (range: 69–110 DDD/1000HS) while parenteral morphine and fentanyl did not register any changes. In the same period of time, total opioid prescription increased in the Oncology Department from 240 to 558 DDD/1000HS. The rate of effectiveness in the three years prior to the implantation of the consultation team was 64% and in the three following years rose to 87%. The rate of improvement prior to the palliative care consultation team was 43% and in the three following years was 64%. A change in opioid prescription was registered after the implementation of the PCCT resulting in an increase in the prescription of parenteral morphine and methadone and a decrease in transdermal fentanyl.

**Conclusion:** Implementation of a PCCT in a University Hospital is associated with a higher and more adequate use of opioids.
Background

Pain relief is one of the key issues for advanced-stage cancer patients and their carers. The World Health Organization (WHO) analgesic ladder recommended the use of weak and strong opioid to treat pain [1]. Data from the early 1990s described that 40% cancer patients do not receive sufficient pain relief [2,3]. However, in the last years there has been a steady increase in the prescription of opioids for the treatment of pain, especially in developed countries, including Spain [4].

There is evidence of the efficiency of interdisciplinary palliative care teams, based in hospitals and cancer centres [5]. A particular kind of these teams are the Palliative Care Consultation Team (PCCT) appeared in the 1970s. A PCCT, usually does not have patient beds under its responsibility but rather it acts in an advisory role to other healthcare professionals and works with the aim of bringing palliative care principles into acute care hospitals [6-8]. The aim of improving palliative care in all hospital patients is achieved by providing direct care by the team and by offering advice to attending doctors [9], as well as by trying to influence the work of other care professionals and staff members [10,11]. The goal is that patients in need of palliative care admitted to any department will receive appropriate care even without the direct intervention of a specialised palliative care team [12,13].

It is estimated that in the USA, 50% of hospitals have a palliative care team, or plan to set one up soon [14]. In Europe, the countries with the most developed Consultation teams are the United Kingdom and France where over 300 services of this type have been identified, corresponding to 35% and 65% of all palliative care units respectively [15]. Data exists which suggest that patients cared for by consultation teams have better assessment of problems and achieve better symptom management [16-18]. Nevertheless, the evaluation of the impact of these consultation teams has been generally limited only to those patients treated directly by the team, without taking into account the whole institution where their influence can be measured on a larger scale.

Pain is one of the most common symptoms occurring in cancer and for many years, opioid prescription has been used as an indicator of appropriate care [19]. In the same way, the impact of the consultation team may be measured in the changes in opioid prescription within the setting where they operate. It is reasonable to expect that their work may result in an increase in the total amount of opioids prescribed in the centre as a whole or at least in those departments targeted by the consultation team. In France, for example, part of the assessment of the hospital consultation teams includes analysing the total amount of opioids prescribed in the hospital where they operate.

In November 2004, a palliative PCCT started its work at the Clínica Universidad de Navarra, a 300 bed teaching hospital. Initially the team’s activity was centred on cancer patients. The PCCT is integrated in the Oncology Department and consisted of two doctors, two nurses, a psychologist and a researcher; it provide support to the whole Oncology Department, composed of 21 oncologists. The PCCT dealt mainly with hospital inpatients, although over time, an increasing number of outpatients were also seen. During the course of its third year, it treated 20% of the 1842 inpatients at the Oncology Department that induced 10896 hospital stays.

There is no known level of opioid prescription which may be considered the ideal for a teaching hospital. In any case, a maximum can be estimated in function of the number of inpatients with severe pain. It can also be assumed that the consultation team has some influence on the type of opioids consumed in the hospital, in that the chosen medications and formulations will be expected to be those considered most effective and safe to meet the patients’ needs.

This study was designed to measure the influence of a PCCT expressed as the impact on the trends of opioid prescription in a University Hospital. To do that, we analyse the patterns in opioid prescription for patients admitted to the Clínica Universidad de Navarra and design indicators of efficiency and effectiveness in pain treatment in cancer patients.

Methods

A study was performed analyzing the amount and type of opioids prescribed to inpatients at the Oncology Department and other Departments at the Clínica Universidad de Navarra, between October 1st 2001 and September 30th 2007, covering the three years prior to and the three years following the setting up of the consultation palliative care team. Inpatients in departments different from Oncology were assigned to a control group. Opioids included in the study were those which can be administered at regular intervals (oral and parenteral morphine, oral and parenteral methadone, oxycodone and transdermal fentanyl). Opioids excluded were transmucous oral fentanyl, (use limited to breakthrough pain), intravenous fentanyl and remifentanil (used limited to diagnostic tests) and transdermal buprenorphine (not yet listed in the Hospital’s Pharmacotherapy Guide).

The Pharmacy Department supplied the data on the quantity and formulations of opioids prescribed and dispensed to inpatients of the Oncology Department. Using this data, the Defined Daily Dose (DDD) for each opioid and for each administration route [20] was calculated. The DDD represents the average daily maintenance dose of a
medication when it used routinely for its main indication and it is expressed as the amount of active ingredient in milligrams, according to its therapeutic equivalence and route of administration (Table 1) [21]. In the calculations for the DDD of transdermal fentanyl consideration was made only of the dose absorbed by the patient in three days and not the dosage in each patch.

The total number of DDD was adjusted to the annual length of stay in the Oncology Department in thousands. The following formula was applied: DDD per 1000 hospital stays divided by the total annual length of stay per year (DDD/1000HS = total DDD × 1000 × annual length of stay\(^{-1}\)) per year.

In order to obtain indicators of efficiency and improvement in pain treatment an estimate on the number of patients admitted with cancer pain was calculated using the rationale that approximately 80% of patients with advanced stages suffer pain [22,23]. Since the Oncology Department already treats patients with diverse stages of the illness, it is reasonable to expect that the percentage of patients suffering from pain might be somewhere between 50% and 80%. For the purpose of this study, the higher figure was chosen. Of these cancer patients suffering pain that requires opioid treatment has been estimated to be around 80% [24,25]. This means that approximately 64% of all patients at the Oncology Department should be ideally treated with opioids.

Following this estimate, as DDD represents the average daily maintenance dose, as long as all those in need do indeed receive opioid treatment the ideal DDD per thousand cancer patients should move around 640. If we take this reference as valid, the efficiency of pain treatment for a cohort of cancer patients can be estimated by calculating the proportion of patients receiving opioids, data of DDD prescribed to Oncology patients are an indicator of pain treatment efficiency. It is expressed in thousands of hospital stays per year and shown in relation to the ideal maximum estimated annual use and can be established as DDD/1000HS × 640\(^{-1}\) (and multiplied × 100 to present the proportion as percentage).

Based on the estimated figure that 64% of cancer inpatients require opioids, it is possible to calculate the percentage of patients who should be receiving this kind of treatment and those who are not as well as estimate how this difference changes every year. This indicator of improvement in pain treatment is estimated as (Final DDD/1000HS - Initial DDD/1000HS) × (640 - Initial DDD/1000HS)\(^{-1}\) (and multiplied × 100 to present the proportion as percentage).

### Results

Table 2 shows the DDD/1000HS for each opioid dispensed by the Pharmacy Department to the Oncology Department during the 2001–2007 period. As the use of meperidine in Oncology was minimal (14–43 units per year), it was excluded from this analysis. During the three years prior to initiation of the PCCT, the total prescription of opioids rose sharply from 240 to 411 DDD/1000HS. After three years it rose to 558 DDD/1000HS. Opioid consumption between 2001 and 2007 in the other Departments was much lower than the one observed in Oncology and demonstrated a steady trend (between 56 and 94 DDD/1000HS) (Table 3).

The indicators for efficiency and improvements are shown on Table 4. At the beginning of the period, the consultation team prescribed opioids to 64% of the estimated patients in need. At the end of the three year period, efficiency had risen to 87%.

The rate of improvement measured as the percentage of patients who began to receive opioids of those estimated in need every year was 12%, 11% and 27% during the three years prior to the consultation team. After the consultation team started, the first year resulted in a negative growth (-7%) although it rose sharply to 54% and 27% the following two years. Overall, the rate of improvement for the three years prior and the three years following the start of the PCCT team was 43% and 64% respectively.

In regards to the trends in opioid prescription at the Oncology Department (Figure 1), the three years prior to beginning the work of the PCCT a steady increase in the prescription of both transdermal fentanyl (from 101 to 222 DDD/1000HS) and parenteral morphine (from 70 to 120 DDD/1000HS) was observed, whilst prescription of oral morphine and methadone did not change. Oxycodeone had still not been released commercially.

After the beginning of the work of the consultation team in 2004, the consumption of oral methadone rose almost ten-fold (from 7 to 68 DDD/1000HS in 2007). In regards

---

Table 1: Equivalence in the Defined Daily Dose (DDD) for different opioids (see reference 20).

| Opioid                | DDD (mg) |
|-----------------------|----------|
| Parenteral morphine   | 30       |
| Oral morphine         | 100      |
| Parenteral methadone  | 25       |
| Oral methadone        | 25       |
| Oral oxycodone        | 75       |
| Transdermal fentanyl  | 1.2      |
to parenteral morphine, during the PCCT’s first year, prescription continued to increase steadily until it shot up the following year (from 120 to 289 DDD/1000HS). Nevertheless, a sharp fall was seen in the use of transdermal fentanyl to levels in line with those of 2001 (from 222 to 103 DDD/1000HS) whilst the prescription of oral morphine and parenteral methadone remained steady. Oxycodone was released commercially in 2004 and its consumption reached 29 DDD/1000HS in 2007. For the rest of the Hospital, the most commonly used opioids were parenteral morphine and transdermal fentanyl, with few changes over the years.

Discussion

Expressing annual hospital opioid prescriptions in terms of the number of DDD per thousand hospital stays is a new way of presenting such data. Previous publications have used other indicators of morphine equivalent doses and generally do not standardise a particular number of individuals [26]. The concept of DDD provides an indicator of the proportion of patients receiving adequate pain treatment and how each type of opioid is used. DDD, a measurement designed for Cross-National Drug Utilization Studies [20], allows for the comparison of results internationally and between centres. In addition, the rate of efficiency described in this study offers an initial estimation of the quality of pain treatment among a group of patients. At the outset of the work of the PCCT, two out of every three patients needing opioids were receiving them. After three years, the percentage had risen to 90%. In regards to the improvement rate, in the three years prior to setting up the consultation team 43% of patients estimated in pain were initiated in opioid treatment, whilst in the three following years this figure rose to 64%. This seems to indicate that the speed at which opioid prescription increased was greater after the PCCT began its work.

It is striking that the start of the PCCT’s activity did not result in an increase in the percentage of patients receiving opioids. Nevertheless, that was the same year which saw the most important change in the type of opioids prescribed: the increasing trend in the use of fentanyl declined but there was no coincident growth in the use of prescribed morphine. This suggests the existence of a subgroup of patients who are being over-treated with transdermal fentanyl. This first effect was soon compensated and the rate of growth for the following year was clearly positive, as if trying to make up lost ground. Notwithstanding, any assessment would require knowledge of the natural behaviour or development of this indicator free from the influence of a consultation team. Neither should it be assumed that the observed changes in opioid prescription are due only to the efficiency of the work of the consultation team. Since they are Oncology patients, it is logical to think that this is an indicator of an improvement in the knowledge and skills on pain management by the oncologists, maintaining the previous trend and also receiving the support of a new PCCT. It is

| Table 2: Prescription of opioids in hospitalized patients in the Oncology Department in Daily Defines Doses per 1000 hospital stays (DDD/1000HS) per year. |
| Opioid            | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
|-------------------|------|------|------|------|------|------|------|
| Parenteral morphine | 70   | 79   | 114  | 120  | 127  | 242  | 289  |
| Oral morphine     | 52   | 43   | 48   | 56   | 55   | 70   | 65   |
| Oxycodone         | 0    | 0    | 0    | 0    | 5    | 20   | 29   |
| Parenteral methadone | 8   | 4    | 5    | 6    | 3    | 0    | 4    |
| Oral methadone    | 9    | 2    | 2    | 7    | 2    | 30   | 68   |
| Transdermal fentanyl | 101 | 160  | 157  | 222  | 184  | 158  | 103  |
| Total DDD/1000HS  | 240  | 288  | 326  | 411  | 396  | 528  | 558  |

| Table 3: Prescription of opioids in hospitalized patients in Departments others than Oncology in Daily Defined Doses per 1000 hospital stays (DDD/1000HS) per year. |
| Opioid            | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
|-------------------|------|------|------|------|------|------|------|
| Parenteral morphine | 43   | 40   | 40   | 44   | 47   | 64   | 61   |
| Oral morphine     | 3    | 1    | 2    | 2    | 2    | 3    | 2    |
| Oxycodone         | 0    | 0    | 0    | 1    | 3    | 2    |
| Parenteral methadone | 4   | 1    | 1    | 0    | 1    |
| Oral methadone    | 1    | 1    | 0    | 1    | 2    |
| Transdermal fentanyl | 18  | 13   | 19   | 24   | 26   | 37   | 26   |
| Total DDD/1000HS  | 69   | 56   | 62   | 71   | 77   | 110  | 94   |
A change was noted in the trend in the use of opioid formulations for Oncology inpatients. Parenteral morphine registered higher utilization than transdermal fentanyl, more than any other opioid and more than oral morphine. Morphine is considered as more appropriate than fentanyl for cancer patients in acute care centres as it allows for quicker adjustments and better management in the prevention of opioid toxicity. The higher utilization of

---

**Table 4: Proposed Indicator of efficiency and ratio of improvement in pain treatment in oncology inpatients**

| Indicators         | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
|--------------------|------|------|------|------|------|------|------|
| Efficiency index   | 37%  | 45%  | 50%  | 64%  | 61%  | 82%  | 87%  |
| Rate of improvement| -    | 12%  | 11%  | 27%  | -7%  | 54%  | 27%  |

(we estimate that 64% of oncology inpatients have to be under opioid treatment: see in the text). Efficiency index \[\text{DDD/1000HS} \times 640^{-1} \times 100\]: Proportion of patients receiving opioid treatments in relation to the total number estimated who should be receiving them. Rate of improvement \[(\text{Final DDD/1000HS} - \text{Initial DDD/1000HS}) \times (640 - \text{Initial DDD/1000HS})^{-1} \times 100\]: Proportion of patients requiring opioids who began to use them in the time considered.

easier to observe the influence of the new team in the changes in the type of opioid used and in the administration routes. The other departments in the hospital, used as control groups in the study, presented a steadily low opioid consumption. This led us to think that the changes in Oncology were not due to institutional bias, nor to changes in the policy of opioid consumption in the hospital as a whole.

---

**Figure 1**

Trends in prescription of the most relevant opioids in hospitalized patients in the Oncology Department, in Daily Defines Doses per 1000 hospital stays (DDD/1000HS) per year. Palliative Care Unit start at 2004.
the parenteral route rather than the oral route for mor-
phine must be revisited under the light of the pharma-
cokinetic data available and concerns over patient
comfort in spite of the fact that the subcutaneous route
offers an opportunity of closer contact with a registered
nurse when pain control is a priority.

Higher utilization of methadone as a second-choice opi-
oid was observed in situations which usually require con-
sultation with the palliative care team, such as patients
with neuropathic pain and cases in which opioid rotation
was indicated [27]. Although methadone registered the
highest percentage increase, the total amount of metha-
done accounted for less than 10% of total opioids pre-
scribed. In a recent study which evaluated the prescription
of long acting opioids between 1996 and 2004 in an Oncology
Centre it was observed that the introduction of a Palliative Care Service coincided with a reduction in the use of fentanyl and an increase in the use of methadone
[28]. The data referring to oxycodone are too premature
does not allow us to draw any conclusions; although
an increase in its consumption in coming years is expected
due to its role in opioid rotation in patients receiving mor-
phine [29]. In general, it may be assumed that the profile of opioid
use from 2004 onwards in this University Hospital reflects
an improvement in the knowledge and skills on the use of
opioids to meet the needs of cancer patients, since this is
where the faster action drug and presentations are
required. This change may be due not only to the direct
effect of the palliative care consultation team (which cares
for only 20% of the patients), but also to the influence it
may have had in the Oncology Department, resulting in
the prescription of the most appropriate drug profile to
suit the needs of the patients.

The data from this study suggests that the implementation
of PCCT in University Hospitals helps optimise the use of
opioids in patients with cancer pain. Further prospective
and comparative surveys on opioids prescription need to
be developed in hospital settings with and without pallia-
tive care consultation teams in order to establish indica-
tors and outcomes of efficiency of these specialized
resources.

This study is aim only to evaluate the effect of a PCCT on
opioid prescription. However, a PCCT should influence
advanced cancer management in other profiles. Although
pain is one and of the more common and relevant symp-
toms in Palliative Care, the origin of patient’s sufferance
transcends pain and the influence of other physical,
social, psycho-emotional and spiritual factors that
requires adequate management can be elicited. The real
effect of a PCCT should be addressed including also its
impact in these other areas.

Conclusion

According to our data, the implementation of a PCCT in a
University Hospital is associated with an increase in total
opioid prescription in cancer patients. This increase is
bound to a change in the pattern of prescription, resulting
in a higher use of parenteral morphine and methadone
and a decrease in transdermal fentanyl. As a whole, these
changes can be interpreted as evidence not only of a
higher but a more adequate use of opioids that allows a
quicker adjustment and a better prevention and manage-
ment of opioid toxicity.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CC participated in the design and coordination of the
study, and in the data analysis and interpretation. MAP
participated in the collection and assembly of data and in
the data analysis and interpretation. AN participated in
the collection and assembly of data. AI participated in the
collection and assembly of data, and interpretation. ASR:
Participated in the design of the study, and in the data
analysis and interpretation. All authors read and approved
the final manuscript.

References

1. World Health Organization: Cancer pain relief and palliative
care. WHO Technical Report Series 1990, 804.
2. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart
JA, Pandya KJ: Pain and its treatment in outpatients with
metastatic cancer. N Engl J Med 1994, 330:592-6.
3. Paregeon KL, Hailey BJ: Barriers to effective cancer pain man-
agement: a review of the literature. J Pain Symptom Manage
1999, 109:281-3.
4. Carvajal A, García del Pozo J, Martín Arias LH, Martín de Diego I,
Rueda AM, Caro-Patón T, Álvarez Requejo A: Changes in the pat-
tern of opioid analgesic consumption in Spain. Med Clin (Barc)
1997, 109:281-3.
5. Higginson IJ, Hearns J: A multicenter evaluation of cancer pain
control by palliative care teams. J Pain Symptom Manage
1997, 14:29-35.
6. Strohscheer I, Verebes J, Samonigg H: Implementation of a Palli-
ative Care Team in an Austrian University Hospital. Support
Care Cancer 2006, 14:795-801.
7. Virik K, Glare P: Profile and evaluation of a palliative medicine
consultation service within a tertiary teaching hospital in
Sydney. J Pain Symptom Manage 2002, 23:17-25.
8. Weissmann DE: Consultations in palliative medicine. Arch Intern
Med 1997, 157:733-7.
9. Cloward P, Meier DE: The palliative care consult team. In Text-
book of Palliative Medicine Edited by: Bruera E, Higginson I, Ripamonti
C, von Gunten C. London: Hodder Arnold; 2006:259-65.
10. Palliative Care in Community Hospitals in Scotland a Framework for Good Practice 2003. Scottish Association of Community Hospitals and Scottish Partnership for Palliative Care [http://www.palliativencarescotland.org.uk/publications/]
11. Fischberg D, Meier DE: Palliative care in hospitals. Clin Geriatr
Med 2004, 20:735-51.
12. Elsayem A, Swint K, Fisch MJ, Palmer JL, Reddy S, Walker P, Zhuko-
vsky D, Knight P, Bruera E: Palliative care inpatient service in a
Comprehensive Cancer Center: clinical and financial outcomes. J Clin Oncol 2004, 22:2008-14.

13. Bascom PB: A hospital-based comfort care team: consultation for seriously ill and dying patients. Am J Hosp Palliat Care 1997, 14:57-60.

14. Pan CX, Morrison RS, Meier DE: How prevalent are hospital-based palliative care programs? Status report and future directions. J Palliat Med 2001, 4:315-24.

15. Centeno C, Clark D, Lynch T, Racafors J, Prall D, De Lima L, Greenwood A, Flores LA, Brasch S, Giordano A, EAPC Task Force: Facts and indicators on palliative care development in 52 countries of the WHO European region: results of an EAPC task force. Palliat Med 2007, 21:463-71.

16. Edmonds PM, Stuttaford JM, Penny J: Do Hospital Palliative Care improve symptom control? Use of modified STAS as an evaluative tool. Palliat Med 1998, 12:345-51.

17. Ellershaw JE, Peat SJ, Boys LC: Assessing the effectiveness of a hospital palliative care team. Palliat Med 1995, 9:45-52.

18. Bruera E, Brennes C, Michaud M, McDonald R: Influence of the pain and symptom control team (PSCT) on the patterns of treatment of pain and other symptoms in a Cancer Center. J Pain Symptom Manage 1989, 4:112-6.

19. World Health Organization: Cancer Pain Relief: With a Guide to Opioid Availability. Geneva: WHO; 1996.

20. ACT/DDD Index 2007 [http://www.whocc.no/atcddd/indexdata base/]

21. Portenoy RK, Lesage P: Management of cancer pain. Lancet 1999, 353:1695-1700.

22. Eisenberg E, Adler R: Consumption of opioids in a hospital setting. What can we learn from a 10 year follow-up? IMAJ 2004, 6:

23. Beuken-van Everdingen MHJ van den, de Rijke JM, Kessels AG, Schouten HC, van Kille M, Patijn J: Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007, 18:1437-49.

24. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA: Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995, 63:65-76.

25. Meusler T, Pietruck C, Radbruch L, Sute P, Lehmann KA, Grond S: Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001, 93:247-57.

26. Bergman U: The history of the Drug Utilization Research Group in Europe. Pharmacoepidemiol Drug Safety 2006, 15:95-8.

27. Terpening CM, Johnson WM: Methadone as an analgesic: a review of the risk and benefits. W V Med J 2007, 103:14-8.

28. Curry EA, Palla S, Hung F, Arbuckle R, Bruera E: Prescribing patterns and purchasing costs of long-acting opioids over nine years at an academic oncology hospital. Am J Health Syst Pharm 2007, 64:1619-25.

29. Riley J, Ross JR, Rutter D, Wells AU, Goller K, du Bois R: No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006, 14:56-64.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-684X/8/2/prepub